A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Conditions
- Solid Tumor, Adult
- Colorectal Cancer
- Non-Small Cell Lung
- NSCLC (Non-small Cell Lung Cancer)
- Cancer
- Colon Cancer
- Rectal Cancer
- Lung Cancer
- CRC
- Head and Neck Squamous Cell Cancer
- HNSCC
- Renal Cell Carcinoma
- RCC
- Kidney Cancer
- Triple Negative Breast Cancer
- TNBC
- Colorectal Adenocarcinoma
Interventions
- BIOLOGICAL: A2B395
- DIAGNOSTIC_TEST: xT CDx with HLA-LOH assay
Sponsor
A2 Biotherapeutics Inc.